Tag: drug safety

Digital Tools and Automation to Streamline Unblinding for Safety Reasons

November 23, 2025November 17, 2025 digi

Digital Tools and Automation to Streamline Unblinding for Safety Reasons Digital Tools and Automation to Streamline Unblinding for Safety Reasons 1. Introduction to Unblinding in Clinical Trials The process of unblinding in clinical trials is a critical aspect, particularly when unanticipated adverse events (AEs) occur that necessitate immediate access to treatment assignments. unblinding plays a…

Unblinding for Safety Reasons

Unblinding for Safety Reasons: End-to-End Compliance Framework for Global Clinical Trials

November 23, 2025November 17, 2025 digi

Unblinding for Safety Reasons: End-to-End Compliance Framework for Global Clinical Trials Unblinding for Safety Reasons: End-to-End Compliance Framework for Global Clinical Trials Introduction to Unblinding in Clinical Trials In the context of good lab clinical trials, unblinding refers to the process of revealing the treatment allocation to clinical trial participants, particularly when safety concerns arise….

Unblinding for Safety Reasons

How to Design Unblinding for Safety Reasons That Meets FDA, EMA and MHRA Expectations

November 23, 2025November 17, 2025 digi

How to Design Unblinding for Safety Reasons That Meets FDA, EMA and MHRA Expectations How to Design Unblinding for Safety Reasons That Meets FDA, EMA and MHRA Expectations Introduction to Unblinding in Clinical Trials Unblinding in clinical trials is a critical process that allows researchers and clinicians to access necessary data regarding the safety and…

Unblinding for Safety Reasons

Unblinding for Safety Reasons in Practice: Step-by-Step Guide for Sponsors and CROs

November 23, 2025November 17, 2025 digi

Unblinding for Safety Reasons in Practice: Step-by-Step Guide for Sponsors and CROs Unblinding for Safety Reasons in Practice: Step-by-Step Guide for Sponsors and CROs Clinical trials are essential for the development of new therapeutics. Within these studies, safety is paramount. Unblinding procedures, particularly for safety reasons, play a crucial role in protecting subjects while ensuring…

Unblinding for Safety Reasons

Data Quality and Reconciliation Controls for Robust Communication with IRB/Regulators

November 23, 2025November 17, 2025 digi

Data Quality and Reconciliation Controls for Robust Communication with IRB/Regulators Data Quality and Reconciliation Controls for Robust Communication with IRB/Regulators Effective communication between clinical trial sponsors, investigators, and Institutional Review Boards (IRBs) or regulators is crucial for the success of any clinical trial. This comprehensive guide, aimed at clinical operations, regulatory affairs, and medical affairs…

Communication with IRB/Regulators

Global Considerations for Communication with IRB/Regulators Across US, EU and UK Programs

November 23, 2025November 17, 2025 digi

Global Considerations for Communication with IRB/Regulators Across US, EU and UK Programs Effective communication with Institutional Review Boards (IRBs) and regulatory agencies is critical to ensuring the integrity and compliance of clinical trials conducted across the US, UK, and EU. Given the complexities of regulatory environments, clinical operations, regulatory affairs, and medical affairs professionals must…

Communication with IRB/Regulators

Future Trends: AI, Automation and Real-World Data in Communication with IRB/Regulators

November 23, 2025November 17, 2025 digi

Future Trends: AI, Automation and Real-World Data in Communication with IRB/Regulators In today’s complex clinical trial landscape, effective communication with Institutional Review Boards (IRBs) and regulators is paramount. As the industry evolves, trends such as artificial intelligence (AI), automation, and the incorporation of real-world data are transforming how clinical research professionals engage with these stakeholders….

Communication with IRB/Regulators

Integrating Communication with IRB/Regulators With DSURs, PBRERs and Risk Management Plans

November 23, 2025November 17, 2025 digi

Integrating Communication with IRB/Regulators With DSURs, PBRERs and Risk Management Plans Integrating Communication with IRB/Regulators With DSURs, PBRERs and Risk Management Plans In the intricate landscape of clinical trials, maintaining robust communication with Institutional Review Boards (IRBs) and regulatory authorities is paramount. This guide serves as a comprehensive tutorial for clinical operations, regulatory affairs, and…

Communication with IRB/Regulators

Vendor and Partner Oversight Considerations in Communication with IRB/Regulators

November 23, 2025November 17, 2025 digi

Vendor and Partner Oversight Considerations in Communication with IRB/Regulators Vendor and Partner Oversight Considerations in Communication with IRB/Regulators The landscape of clinical research, particularly concerning metformin clinical trials, has brought to light the critical need for effective communication with Institutional Review Boards (IRBs) and regulatory bodies. A robust oversight mechanism over vendors and partners is…

Communication with IRB/Regulators

Training Investigators and Sites to Execute Communication with IRB/Regulators Reliably

November 23, 2025November 17, 2025 digi

Training Investigators and Sites to Execute Communication with IRB/Regulators Reliably Training Investigators and Sites to Execute Communication with IRB/Regulators Reliably Introduction to Regulatory Communications in Clinical Trials Effective communication between investigators, clinical sites, and Institutional Review Boards (IRBs) is crucial for the successful execution of clinical trials, particularly in the context of bladder cancer clinical…

Communication with IRB/Regulators